相关实验视频

Updated: Jul 22, 2025

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

在前性痴呆症中分析和临床验证血液中Progranulin ELISA

Francisco Meda¹, Joel Simrén^1,2, Barbara Borroni³

¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Clinical chemistry and laboratory medicine

|July 21, 2023

概括

这项研究验证了一种商业化的progranulin套件,用于检测与前性痴呆症 (FTD) 相关的花素 (GRN) 基因突变. 该测定准确地识别GRN突变载体,有助于诊断和潜在的治疗监测.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
生物化学生物化学

背景情况:

异性GRN突变会导致前列腺素 (PGRN) 脱,这是前性痴呆症 (FTD) 的已知危险因素.
精确测量PGRN水平对于诊断GRN相关的FTD和监测治疗干预措施至关重要.

研究的目的:

进行用于常规临床使用的商业益格拉努林试验的分析和临床验证.
评估progranulin套件在区分GRN突变载体与健康个体和其他神经退行性疾病患者的诊断性能.

主要方法:

分析验证包括测试试剂精度,选择性,测量范围,稀释线性,干扰和样品稳定性的测试.
临床验证测量了对照组,GRN突变载体,C9orf72突变载体和患有各种神经退行性疾病的患者的血PGRN水平.

主要成果:

益格拉努林测定显示出极好的精度 (CV <7%) 和稳定性在各种条件下.
该试验准确地将GRN突变载体与对照物和非载体区分开来,在57μg/L的切线下,具有97%的灵敏度和100%的特异性.

结论:

商用progranulin套件表现出强大的分析和诊断性能,适合临床实验室实施.
这种测定有助于识别潜在的GRN突变载体,指导进一步的患者评估,并可能监测新的PGRN向疗法.

关键词:

前性痴呆症前性痴呆症益格拉努林是一种前列腺素.验证验证的时间

更多相关视频

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

相关概念视频